Drug-resistant EGFR mutations promote lung cancer by stabilizing interfaces in ligand-free kinase-active EGFR oligomers

R. Sumanth Iyer,Sarah R. Needham,Ioannis Galdadas,Benjamin M. Davis,Selene K. Roberts,Rico C. H. Man,Laura C. Zanetti-Domingues,David T. Clarke,Gilbert O. Fruhwirth,Peter J. Parker,Daniel J. Rolfe,Francesco L. Gervasio,Marisa L. Martin-Fernandez

DOI: https://doi.org/10.1038/s41467-024-46284-x

IF: 16.6

2024-03-19

Nature Communications

Abstract:Abstract The Epidermal Growth Factor Receptor (EGFR) is frequently found to be mutated in non-small cell lung cancer. Oncogenic EGFR has been successfully targeted by tyrosine kinase inhibitors, but acquired drug resistance eventually overcomes the efficacy of these treatments. Attempts to surmount this therapeutic challenge are hindered by a poor understanding of how and why cancer mutations specifically amplify ligand-independent EGFR auto-phosphorylation signals to enhance cell survival and how this amplification is related to ligand-dependent cell proliferation. Here we show that drug-resistant EGFR mutations manipulate the assembly of ligand-free, kinase-active oligomers to promote and stabilize the assembly of oligomer-obligate active dimer sub-units and circumvent the need for ligand binding. We reveal the structure and assembly mechanisms of these ligand-free, kinase-active oligomers, uncovering oncogenic functions for hitherto orphan transmembrane and kinase interfaces, and for the ectodomain tethered conformation of EGFR. Importantly, we find that the active dimer sub-units within ligand-free oligomers are the high affinity binding sites competent to bind physiological ligand concentrations and thus drive tumor growth, revealing a link with tumor proliferation. Our findings provide a framework for future drug discovery directed at tackling oncogenic EGFR mutations by disabling oligomer-assembling interactions.

multidisciplinary sciences

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to understand how EGFR mutations in non - small - cell lung cancer (NSCLC) promote tumor growth, especially how these mutations enhance cell survival signals by stabilizing ligand - unbound, kinase - active EGFR oligomers. Specifically, the researchers focused on how drug - resistant EGFR mutations manipulate ligand - free, kinase - active oligomer assembly to promote and stabilize the assembly of active dimer subunits in these oligomers, thereby bypassing the need for ligand binding. This helps to reveal the mechanisms of tumor proliferation and provides a framework for future drug discovery targeting oncogenic EGFR mutations. The key points of the paper include: - **Problem background**: EGFR mutations occur frequently in non - small - cell lung cancer. Although they have been successfully targeted by tyrosine kinase inhibitors (TKIs), patients will eventually develop drug resistance. - **Research objective**: To study how drug - resistant EGFR mutations promote the development of lung cancer by stabilizing ligand - unbound, kinase - active EGFR oligomers, and the relationship between this mechanism and ligand - dependent cell proliferation. - **Methods**: Using super - resolution fluorescence localization imaging with photobleaching (FLImP) technology, combined with large - scale molecular dynamics simulations, an assembly model of EGFR oligomers in the ligand - unbound state was constructed. - **Main findings**: Wild - type EGFR, T766M - EGFR and Ex20Ins - EGFR share a ligand - unbound heteromeric oligomer structure, which contains a scaffold composed of H2Hect/2xkin monomers and B2Bect/H2Hkin dimer subunits fixed by the transmembrane interface, and these scaffolds regulate the St2Stect/Asymkin dimer subunits in the extracellular part. NSCLC mutations increase the number and stability of St2Stect/Asymkin dimer subunits by stabilizing the auxiliary kinase interface, thus explaining the reason for the increased mutation - dependent ligand - free phosphorylation. Through these studies, the authors provide new insights into how EGFR mutations cause lung cancer and a theoretical basis for the development of new treatment strategies.

Drug-resistant EGFR mutations promote lung cancer by stabilizing interfaces in ligand-free kinase-active EGFR oligomers

L858R/L718Q and L858R/L792H Mutations of EGFR Inducing Resistance Against Osimertinib by Forming Additional Hydrogen Bonds

Perturbation of the Mutated Egfr Interactome Identifies Vulnerabilities and Resistance Mechanisms

Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer

Structural insights into drug development strategy targeting EGFR T790M/C797S

Discovery of N-((3r,4r)-4-Fluoro-1-(6-((3-Methoxy-1-Methyl-1h-Pyrazol-4-Yl)Amino)-9-M Ethyl-9h-Purin-2-Yl)Pyrrolidine-3-Yl)Acrylamide (Pf-06747775) Through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic Egfr Mutants with Selectivity over Wild-Type Egfr

Geometrical Features of Epidermal Growth Factor Receptor-Related Dimers Reveal the Mechanisms of Drug Resistance in Lung Cancer Patients

Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer

Structures Of Lung Cancer-Derived Egfr Mutants And Inhibitor Complexes: Mechanism Of Activation And Insights Into Differential Inhibitor Sensitivity

Structural insights into characterizing binding sites in EGFR kinase mutants

EGFR-TKI Resistance in NSCLC Patients: Mechanisms and Strategies.

EGFR kinase mutations in NSCLC: Unexpected structural and kinetic insights into the mechanism of the T790M resistance mutation and its inhibition by irreversible inhibitors including HKI-272

The T790m Mutation in Egfr Kinase Causes Drug Resistance by Increasing the Affinity for Atp

Contribution of EGFR and ErbB-3 Heterodimerization to the EGFR Mutation-Induced Gefitinib- and Erlotinib-Resistance in Non-Small-Cell Lung Carcinoma Treatments

Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer

AXL and error-prone DNA replication confer drug resistance and offer strategies to treat EGFR-mutant lung cancer

Epidermal Growth Factor Receptor–Mutant Lung Cancer: New Drugs, New Resistance Mechanisms, and Future Treatment Options

Multiple post-translational modifications ensure EGFR functionality: Potential therapeutic targets to overcome its drug-resistance mutations

Current Therapeutic Strategies and Prospects for EGFR Mutation-Positive Lung Cancer Based on the Mechanisms Underlying Drug Resistance

Loss of Activating EGFR Mutant Gene Contributes to Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer Cells

EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance